Praluzatamab ravtansine

雷普罗妥单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePraluzatamab ravtansine
Drug Alias NameCX-2009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD166
TargetsActivated leukocyte cell adhesion molecule
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunogen IncCytomx Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytomx Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A